10x Genomics (NASDAQ:TXG) Given New $55.00 Price Target at Barclays
10x Genomics (NASDAQ:TXG – Free Report) had its target price upped by Barclays from $45.00 to $55.00 in a report published on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Several other research firms also recently issued reports on TXG. Guggenheim initiated coverage on shares of 10x Genomics in a research […]
More Stories
NVIDIA Co. (NASDAQ:NVDA) is Formidable Asset Management LLC’s 5th Largest Position
Formidable Asset Management LLC decreased its holdings in NVIDIA Co. (NASDAQ:NVDA – Free Report) by 0.4% in the 4th quarter,...
NVIDIA Co. (NASDAQ:NVDA) Shares Purchased by Invst LLC
Invst LLC boosted its position in NVIDIA Co. (NASDAQ:NVDA – Free Report) by 1.7% in the fourth quarter, according to...
University of Texas Texas AM Investment Management Co. Has $22.66 Million Stake in NVIDIA Co. (NASDAQ:NVDA)
University of Texas Texas AM Investment Management Co. cut its stake in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report)...
ARQ Wealth Advisors LLC Decreases Stake in NVIDIA Co. (NASDAQ:NVDA)
ARQ Wealth Advisors LLC lowered its holdings in NVIDIA Co. (NASDAQ:NVDA – Free Report) by 6.3% in the 4th quarter,...
Two Sigma Investments LP Reduces Stock Holdings in Luxfer Holdings PLC (NYSE:LXFR)
Two Sigma Investments LP decreased its holdings in Luxfer Holdings PLC (NYSE:LXFR – Free Report) by 1.6% in the fourth...
Two Sigma Advisers LP Raises Stock Holdings in Wipro Limited (NYSE:WIT)
Two Sigma Advisers LP grew its stake in Wipro Limited (NYSE:WIT – Free Report) by 143.1% during the 4th quarter,...